Stock Price Movement and Market Context
On 2 Mar 2026, Link Pharma Chem Ltd recorded its lowest price in the past year at Rs.23.5, down from its 52-week high of Rs.42.8. Despite outperforming its sector by 1.72% on the day, the stock remains below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward momentum.
In comparison, the broader market index, Sensex, experienced a volatile session, recovering from a gap down opening of -2,743.46 points to close at 80,156.71, down 1.39%. The Sensex trades below its 50-day moving average, though the 50DMA remains above the 200DMA, signalling mixed market conditions.
Over the past year, Link Pharma Chem Ltd’s stock has declined by 20.46%, contrasting sharply with the Sensex’s positive return of 9.51%. This divergence highlights the company’s relative underperformance within the broader market environment.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Financial Performance and Profitability Metrics
Link Pharma Chem Ltd’s long-term financial indicators reveal ongoing pressures. The company has experienced a compound annual growth rate (CAGR) decline of 27.15% in operating profits over the last five years, signalling contraction in core earnings capacity. This weak growth trajectory has contributed to the stock’s subdued market valuation.
The company’s ability to service debt remains constrained, with an average EBIT to interest coverage ratio of 0.68. This ratio indicates limited earnings buffer to meet interest obligations, raising concerns about financial flexibility.
Profitability metrics also reflect challenges, with an average return on equity (ROE) of 4.94%, suggesting modest returns generated on shareholders’ funds. Additionally, the return on capital employed (ROCE) stands at -0.5%, underscoring inefficiencies in capital utilisation.
Despite these concerns, recent financial results show some positive trends. Net sales for the latest six months reached Rs.13.02 crores, growing at 28.40%. The profit after tax (PAT) for the nine-month period improved to Rs.0.49 crore, while quarterly PBDIT hit a high of Rs.0.69 crore. These figures indicate pockets of operational improvement amid broader challenges.
Valuation and Market Position
From a valuation perspective, Link Pharma Chem Ltd is trading at a discount relative to its peers’ historical averages. The enterprise value to capital employed ratio is 1, which may be considered attractive given the company’s current financial profile. The price-to-earnings-to-growth (PEG) ratio stands at 0.1, reflecting the market’s pricing of the company’s earnings growth potential relative to its stock price.
Nevertheless, the stock’s consistent underperformance against benchmarks remains a concern. Over the last three years, the company has underperformed the BSE500 index in each annual period, reinforcing the trend of relative weakness.
Considering Link Pharma Chem Ltd? Wait! SwitchER has found potentially better options in Commodity Chemicals and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Commodity Chemicals + beyond scope
- - Top-rated alternatives ready
Shareholding and Market Capitalisation
The majority shareholding in Link Pharma Chem Ltd is held by promoters, maintaining a concentrated ownership structure. The company’s market capitalisation grade is rated 4, reflecting its micro-cap status within the commodity chemicals sector.
The company’s Mojo Score currently stands at 32.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 19 May 2025. This adjustment indicates a slight improvement in the company’s overall assessment, though the outlook remains cautious.
Summary of Key Performance Indicators
To summarise, Link Pharma Chem Ltd’s key financial and market metrics as of 2 Mar 2026 are:
- 52-week low price: Rs.23.5
- 52-week high price: Rs.42.8
- One-year stock return: -20.46%
- Sensex one-year return: +9.51%
- Operating profit CAGR (5 years): -27.15%
- EBIT to interest coverage ratio (average): 0.68
- Return on equity (average): 4.94%
- Return on capital employed: -0.5%
- Net sales growth (latest six months): 28.40%
- PAT (9 months): Rs.0.49 crore
- Quarterly PBDIT: Rs.0.69 crore
- Mojo Score: 32.0
- Mojo Grade: Sell (upgraded from Strong Sell)
These figures illustrate the company’s ongoing challenges in generating consistent profitability and growth, despite some recent improvements in sales and earnings.
Technical and Market Outlook
Technically, the stock’s position below all major moving averages suggests continued downward pressure. The gap between the current price and the 52-week high of Rs.42.8 emphasises the extent of the decline over the past year.
While the stock outperformed its sector on the day by 1.72%, this was insufficient to reverse the broader trend of underperformance relative to the Sensex and BSE500 indices.
Conclusion
Link Pharma Chem Ltd’s fall to a 52-week low of Rs.23.5 reflects a combination of weak long-term growth, limited profitability, and financial constraints. Although recent sales and profit figures show some positive movement, the company continues to face challenges in regaining market confidence and improving its financial health. The stock’s valuation discounts these factors, and its relative underperformance against benchmarks remains a notable feature of its recent history.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
